Journal of Hematology & Oncology

Article	Citations
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	837
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	818
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	790
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	773
Recent advances in targeting protein degradation for tumor immunotherapy	741
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	516
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	491
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	479
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	395
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	386
Cancer vaccines: current status and future directions	368
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	365
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	336
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases	323
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	308
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	298
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	289
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	276
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	274
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	271
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	262
Landscape of biallelic DNMT3A mutant myeloid neoplasms	254
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	251
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	241
Ferroptosis: principles and significance in health and disease	233

Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	224
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors	219
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	216
Personalized nanovaccines for treating solid cancer metastases	210
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	206
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	202
Recent advances in therapeutic strategies for non-small cell lung cancer	201
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	188
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	187
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	182
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?	179
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	179
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies	179
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	178
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	177
3D chromatin architecture and transcription regulation in cancer	177
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	176
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	176
Small RNA modifications: regulatory molecules and potential applications	168
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	164
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer	161
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	159
Multiple myeloma risk linked to DNA damage response genes	158
Recent advances in targeted strategies for triple-negative breast cancer	154
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	151
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	148
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	147
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	147
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	144
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	143
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	141
A single-cell and spatially resolved atlas of human osteosarcomas	141
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	140
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	139
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials	139
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	135
Target neutrophil heterogeneity and plasticity in cancer	134
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	133
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	133
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects	128
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	128
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	124
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting	124
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	122
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	121
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	120
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	120
The functional and clinical roles of liquid biopsy in patient-derived models	117
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	117
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	117

Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer	117
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies	115
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting	110
Echinomycin as a promising therapeutic agent against KSHV-related malignancies	110
Worked to the bone: antibody-based conditioning as the future of transplant biology	109
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting	109
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial	108
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis	106
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives	103
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II	102
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination	100
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies	99
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function	98
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives	97
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy	97
Gastric cancer treatment: recent progress and future perspectives	95
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders	93
Challenges and new technologies in adoptive cell therapy	93
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	91
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	91
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	89
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	88
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	87
Targeting GPRC5D for multiple myeloma therapy	87
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	85
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	83
Metabolic reprogramming in the tumor microenvironment of liver cancer	82
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	81
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	81
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	80
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	80
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	79
Advances in targeting histone deacetylase for treatment of solid tumors	79
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	78
PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy	76
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	76
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer	74
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	73
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	73
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	72
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	71
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	69
Correction: Immunosenescence: a key player in cancer development	68
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy	68
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	68
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	67
Racial disparities in clonal hematopoiesis and their impact on hematologic malignancies	66
C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction	66
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry	66
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation	65
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears	65
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies	64
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application	64
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	63
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021	63
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lympho	63
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma	63
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities	62
Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant	61
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	61
Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation	61
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades	60
Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study	60
The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications	59
Targeting inflammation as cancer therapy	59
Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies	59
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy	58
Integrated clinical and proteomic-based model for diagnostic and prognostic prediction in pRCC	56
Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies	56
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study	53
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics	52
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies	52
A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors	52
Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives	50
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting	49
Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants	49
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting	48
Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma	48
Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting	47
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease	47

Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead	47
Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolyt	46
Mitophagy’s impacts on cancer and neurodegenerative diseases: implications for future therapies	46
Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease	46
Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types	46
Genitourinary cancers updates: highlights from ASCO 2023	45
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy	45
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma	44
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis	44
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed pri	44
CBX3 confers ferroptosis resistance during blood-borne metastasis	44
Molecularly targeted therapy and immunotherapy in leukemias	43
Novel strategies for cancer immunotherapy: counter-immunoediting therapy	42
A novel tRNA-derived fragment tRF-3022b modulates cell apoptosis and M2 macrophage polarization via binding to cytokines in colorectal cancer	42
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2	41
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy	41
Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies	41
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting	41
CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial	40
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients	40
Implementing generative artificial intelligence in precision oncology: safety, governance, and significance	40
Disruption of the sorcin‒PAX5 protein‒protein interaction induces ferroptosis by promoting the FBXL12-mediated ubiquitination of ALDH1A1 in pancreatic cancer	40
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium	39
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma	36
Involvement of inflammasomes in tumor microenvironment and tumor therapies	36
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena	36
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents	36
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021	35
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells	34
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant	34
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia	34
Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance	34
The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior	33
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated resu	33
Consensus, debate, and prospective on pancreatic cancer treatments	32
Non-canonical small noncoding RNAs in the plasma extracellular vesicles as novel biomarkers in gastric cancer	31
Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis	31
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy	30
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR	29
Liquid biopsy: current technology and clinical applications	29
A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes	29
Recent advances in therapeutic strategies for triple-negative breast cancer	29
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression	29
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers	28
PD-1 blockade immunotherapy as a successful rescue treatment for disseminated adenovirus infection after allogeneic hematopoietic stem cell transplantation	28
Correction: The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	28
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation	28
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022	27
LncRNA-encoded peptides in cancer	27
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair	27
Targeting FGFR for cancer therapy	27
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial	27
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality	27
Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities	27
Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013	26
Lipid-based nanosystems: the next generation of cancer immune therapy	26
The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer	26
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting	25
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial	25
Emerging advances in CAR-T therapy for solid tumors: latest clinical trial updates from 2025 ASCO annual meeting	25
Retraction Note: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor	25
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment	25
In vivo CAR-T cell therapy: latest updates from 2025 ASH annual meeting	24
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia	24
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA	24
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021	24
The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives	24
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment	24
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies	23
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies	23
Necroptosis in cancer: insight from epigenetic, post-transcriptional and post-translational modifications	23
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors	23
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Conso	22
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia	22
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia	22
Recent advances in S-palmitoylation and its emerging roles in human diseases	22
Protein degradation: expanding the toolbox to restrain cancer drug resistance	22
Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia	22
Emerging evidence and treatment paradigm of non-small cell lung cancer	21
Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide	21
Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL	21
FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study	21
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells	21
Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	21
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets	21
FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma	21
Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia	20
Correction: CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells	20
IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders	20
CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting	20
Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization	20
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study	20
FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion	19
Global cancer statistics for adolescents and young adults: population based study	19
Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity	19